DMARDs

Generic Name: DMARDs

Clinical Trials

Cortisol Circadian Rhythm in Patients With RA

Recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: DMARDs

First Posted Date: 2023-01-04

Last Posted Date: 2023-01-04

Lead Sponsor: National and Kapodistrian University of Athens

Target Recruit Count: 50

Registration Number: NCT05671627

Locations: 🇬🇷
Laiko General Hospital, Athens, Greece

Immunosuppressant Combined With Pirfenidone in CTD-ILD

Phase 4

Active, not recruiting

Conditions: Interstitial Lung Disease
Pirfenidone
Connective Tissue Diseases

Interventions: Drug: Pirfenidone
Drug: DMARDs

First Posted Date: 2021-06-16

Last Posted Date: 2023-11-18

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 200

Registration Number: NCT04928586

Locations: 🇨🇳
Qilu Hospital, Jinan, Shandong, China

PANLAR's Latin American Registry of Rheumatic Patients Treated With Jak Inhibitors

Conditions: Spondyloarthritis
Arthritis, Psoriatic
Arthritis, Rheumatoid

Interventions: Drug: JAK Inhibitor
Drug: DMARDs
Drug: biologic DMARDs

First Posted Date: 2021-03-29

Last Posted Date: 2021-03-29

Lead Sponsor: Liga Panamericana de Asociaciones de Reumatologia (PANLAR)

Target Recruit Count: 3000

Registration Number: NCT04821206

Locations: 🇦🇷
Hospital Italiano de Buenos Aires, Caba, Buenos Aires, Argentina
🇦🇷
Nicolas Marin Zucaro, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina

Optimal MTX Dose With Folic Acid Randomized Case-control Trial

Phase 4

Conditions: Rheumatoid Arthritis

Interventions: Drug: MTX
Drug: Folic Acid
Drug: DMARDs

First Posted Date: 2019-08-26

Last Posted Date: 2019-08-26

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 160

Registration Number: NCT04066803

Locations: 🇨🇳
the 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Rheumatoid Arthritis Memory B Cells and Abatacept

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept
Drug: DMARDs

First Posted Date: 2018-08-31

Last Posted Date: 2024-07-03

Lead Sponsor: NYU Langone Health

Target Recruit Count: 25

Registration Number: NCT03652961

Locations: 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Human Umbilical Cord-Mesenchymal Stem Cells for Rheumatoid Arthritis

Phase 1

Conditions: Rheumatoid Arthritis

Interventions: Biological: hUC-MSC + DMARDs
Drug: DMARDs

First Posted Date: 2015-12-31

Last Posted Date: 2016-05-24

Lead Sponsor: Shenzhen Hornetcorn Bio-technology Company, LTD

Target Recruit Count: 40

Registration Number: NCT02643823

Locations: 🇨🇳
The Fourth People's Hospital of Shenzhen, Shenzhen, Guangdong, China

An Observational Study of Infliximab in Participants Suffering From Ankylosing Spondylitis With Hip Involvement

Terminated

Conditions: Spondylitis, Ankylosing

Interventions: Drug: Infliximab
Drug: DMARDs
Drug: NSAIDs

First Posted Date: 2014-11-18

Last Posted Date: 2017-11-01

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 76

Registration Number: NCT02293681

A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab
Drug: DMARDs
Drug: Oral Corticosteroids
Drug: Methotrexate

First Posted Date: 2014-01-28

Last Posted Date: 2018-12-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 162

Registration Number: NCT02046603

Locations: 🇬🇧
Aberdeen Royal Infirmary, Aberdeen, United Kingdom
🇬🇧
Royal Sussex County Hospital; Clinical Investigation Research Unit, Brighton, United Kingdom
🇬🇧
University Hospital of Wales; Dept of Rhematology, Cardiff, United Kingdom

and more 35 locations

A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab
Drug: DMARDs

First Posted Date: 2013-09-13

Last Posted Date: 2017-07-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 227

Registration Number: NCT01941940

Locations: 🇮🇹
Osp S. Maria Misericordia Dip. Medicina Clinica Sperimentale Cattedra Reumatologia, Perugia, Umbria, Italy
🇮🇹
Uni Degli Studi Di L Aquila; Cattedra Di Reumatologia - Dept. Di Medicina Interna E San, Coppito, Abruzzo, Italy
🇮🇹
Ospedale Regionale Torrette; SOD Clinica Medica del Dipartimento di Medicina Interna e Specialisti, Ancona, Marche, Italy

and more 46 locations

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With DMARDs Versus DMARDs Alone in Patients With Rheumatoid Arthritis

Phase 3

Conditions: Combination With DMARDs

Interventions: Drug: DMARDs

First Posted Date: 2013-02-08

Last Posted Date: 2018-04-17

Lead Sponsor: Mycenax Biotech Inc.

Target Recruit Count: 98

Registration Number: NCT01787149

Locations: 🇨🇳
Mackay Memorial Hospital Institutional, Taipei, Taiwan
🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳
Cheng Hsin General Hospital, Taipei, Taiwan

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy